Pfizer agreed to license “in vivo” CAR-T assets from Starna Therapeutics as the pharma pushes further into cell-therapy approaches designed to avoid ex vivo manufacturing bottlenecks. The deal covers three preclinical autoimmune programs outside Greater China, with additional licensing options tied to technology use across inflammation, immunology, and oncology. Under the terms disclosed, Pfizer will pay Starna $330 million upfront, with up to $2.3 billion more in development and commercial milestones. Starna is also eligible for royalties on any approved products. The arrangement signals continued industry focus on streamlining CAR-T production by reprogramming cells inside the body. The technology is still early-stage, but recent corporate activity across the sector suggests in vivo formats are becoming a key strategic differentiator for next-generation immunotherapies.
Get the Daily Brief